Identification

Name
Lumiracoxib
Accession Number
DB01283
Type
Small Molecule
Groups
Approved, Investigational
Description

Lumiracoxib is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.

Structure
Thumb
Synonyms
  • 2-((2-chloro-6-Fluorophenyl)amino)-5-methylbenzeneacetic acid
  • COX 189
  • COX189
  • Lumiracoxibum
  • Prexige
External IDs
COX-189
International/Other Brands
Prexige (Novartis)
Categories
UNII
V91T9204HU
CAS number
220991-20-8
Weight
Average: 293.721
Monoisotopic: 293.061884577
Chemical Formula
C15H13ClFNO2
InChI Key
KHPKQFYUPIUARC-UHFFFAOYSA-N
InChI
InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)
IUPAC Name
2-{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid
SMILES
CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1

Pharmacology

Indication

For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.

Structured Indications
Not Available
Pharmacodynamics

Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.

Mechanism of action

The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Rapidly absorbed following oral administration, with an absolute oral bioavailablity of 74%.

Volume of distribution
Not Available
Protein binding

Highly bound to plasma proteins (>= 98%).

Metabolism

Hepatic oxidation and hydroxylation via CYP2C9. Three major metabolites have been identified in plasma: 4'-hydroxy-lumiracoxib, 5-carboxy-lumiracoxib, and 4'-hydroxy-5-carboxy-lumiracoxib.

Route of elimination
Not Available
Half life

Terminal half-life is approximately 4 hours.

Clearance
Not Available
Toxicity

Single oral doses in mice and rats resulted in mortality and/or moribundity at doses of 600 mg/kg and 500 mg/kg, respectively. Single intraperitoneal doses in mice and rats results in mortality/moribundity at 750 mg/kg and 1000 mg/kg, respectively. The maximum non-lethal single oral and intraperitoneal dose in mouse was 300 mg/kg and 250 mg/kg, respectively. In the rat it was 150 mg/kg and 250 mg/kg, respectively.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Lumiracoxib Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabLumiracoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Lumiracoxib can be increased when it is combined with Abiraterone.Approved
AcebutololLumiracoxib may decrease the antihypertensive activities of Acebutolol.Approved
AcenocoumarolLumiracoxib may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Lumiracoxib.Approved, Vet Approved
AclarubicinLumiracoxib may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Lumiracoxib.Experimental
AlclometasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Alendronic acid.Approved
AliskirenLumiracoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololLumiracoxib may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Lumiracoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Amcinonide.Approved
AmikacinLumiracoxib may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideLumiracoxib may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Lumiracoxib can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinLumiracoxib may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodLumiracoxib may increase the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with anecortave acetate.Investigational
annamycinLumiracoxib may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
Antithrombin III humanLumiracoxib may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanLumiracoxib may increase the anticoagulant activities of Apixaban.Approved
ApramycinLumiracoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
AprepitantThe metabolism of Lumiracoxib can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinLumiracoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinLumiracoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanLumiracoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArmodafinilThe metabolism of Lumiracoxib can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololLumiracoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Atamestane.Investigational
AtenololLumiracoxib may decrease the antihypertensive activities of Atenolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lumiracoxib.Approved
AzithromycinThe metabolism of Lumiracoxib can be decreased when combined with Azithromycin.Approved
BalsalazideLumiracoxib may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminLumiracoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololLumiracoxib may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinLumiracoxib may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lumiracoxib.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Lumiracoxib.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lumiracoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololLumiracoxib may decrease the antihypertensive activities of Betaxolol.Approved
BevantololLumiracoxib may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
BisoprololLumiracoxib may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinLumiracoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololLumiracoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Lumiracoxib can be decreased when combined with Bortezomib.Approved, Investigational
BucindololLumiracoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Budesonide.Approved
BufuralolLumiracoxib may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideLumiracoxib may decrease the diuretic activities of Bumetanide.Approved
BupranololLumiracoxib may decrease the antihypertensive activities of Bupranolol.Approved
CaffeineThe metabolism of Lumiracoxib can be decreased when combined with Caffeine.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Lumiracoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Lumiracoxib.Experimental
CapecitabineThe metabolism of Lumiracoxib can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Lumiracoxib.Approved
CarbamazepineThe metabolism of Lumiracoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Lumiracoxib.Approved
CarteololLumiracoxib may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolLumiracoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CeliprololLumiracoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Lumiracoxib can be increased when it is combined with Ceritinib.Approved
CertoparinLumiracoxib may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloramphenicolThe metabolism of Lumiracoxib can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Vet Approved
ChlorotrianiseneLumiracoxib may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Lumiracoxib.Approved
CholecalciferolThe metabolism of Lumiracoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lumiracoxib.Approved
CimetidineThe metabolism of Lumiracoxib can be decreased when combined with Cimetidine.Approved
CinoxacinLumiracoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the antiplatelet activities of Lumiracoxib.Approved
Citric AcidLumiracoxib may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clodronic Acid.Approved, Investigational, Vet Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Lumiracoxib.Vet Approved
CloranololLumiracoxib may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneLumiracoxib may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Lumiracoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Lumiracoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensLumiracoxib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Lumiracoxib can be decreased when combined with Crisaborole.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lumiracoxib.Experimental
CyclosporineLumiracoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Lumiracoxib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateLumiracoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Lumiracoxib can be decreased when it is combined with Dabrafenib.Approved
DaidzeinLumiracoxib may increase the thrombogenic activities of Daidzein.Experimental
DalteparinLumiracoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidLumiracoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Lumiracoxib.Investigational
DarexabanLumiracoxib may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinLumiracoxib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Lumiracoxib.Experimental
DelavirdineThe metabolism of Lumiracoxib can be decreased when combined with Delavirdine.Approved
DesirudinLumiracoxib may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Lumiracoxib.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Lumiracoxib.Approved, Investigational
DextranLumiracoxib may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Lumiracoxib may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Lumiracoxib may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Lumiracoxib may increase the anticoagulant activities of Dextran 75.Approved
DibekacinLumiracoxib may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DicoumarolLumiracoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolLumiracoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolLumiracoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DiflorasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lumiracoxib.Approved
DihydrostreptomycinLumiracoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Lumiracoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lumiracoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Lumiracoxib.Approved
DiphenadioneLumiracoxib may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Lumiracoxib can be decreased when combined with Dosulepin.Approved
DoxorubicinLumiracoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneLumiracoxib may increase the hyperkalemic activities of Drospirenone.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Lumiracoxib.Approved
Edetic AcidLumiracoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanLumiracoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Lumiracoxib can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lumiracoxib.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Lumiracoxib.Approved
EnoxacinLumiracoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinLumiracoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Lumiracoxib.Experimental
EpanololLumiracoxib may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolLumiracoxib may increase the thrombogenic activities of Epimestrol.Experimental
EpirubicinLumiracoxib may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneLumiracoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lumiracoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Lumiracoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Equilin.Approved
EquolLumiracoxib may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Lumiracoxib can be decreased when combined with Eslicarbazepine acetate.Approved
EsmololLumiracoxib may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Lumiracoxib can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolLumiracoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolLumiracoxib may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
EstroneLumiracoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Estrone sulfate.Approved
Etacrynic acidLumiracoxib may decrease the diuretic activities of Etacrynic acid.Approved
Ethinyl EstradiolLumiracoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateLumiracoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Etidronic acid.Approved
EtoperidoneEtoperidone may increase the antiplatelet activities of Lumiracoxib.Withdrawn
EtravirineThe metabolism of Lumiracoxib can be decreased when combined with Etravirine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Lumiracoxib.Vet Approved
Ferulic acidLumiracoxib may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lumiracoxib.Approved, Investigational
FleroxacinLumiracoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Lumiracoxib.Approved, Withdrawn
FloxuridineThe metabolism of Lumiracoxib can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with fluasterone.Investigational
FluconazoleThe metabolism of Lumiracoxib can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fludrocortisone.Approved
FluindioneLumiracoxib may increase the anticoagulant activities of Fluindione.Investigational
FlumequineLumiracoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Flumethasone.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Lumiracoxib.Approved
FluorouracilThe metabolism of Lumiracoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Lumiracoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Flurandrenolide.Approved
FluvastatinThe metabolism of Lumiracoxib can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Lumiracoxib can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Lumiracoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxLumiracoxib may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumLumiracoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Lumiracoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lumiracoxib.Approved
FosphenytoinThe metabolism of Lumiracoxib can be increased when combined with Fosphenytoin.Approved
FramycetinLumiracoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideLumiracoxib may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateLumiracoxib may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinLumiracoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinLumiracoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Lumiracoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Lumiracoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinLumiracoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinLumiracoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinLumiracoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinLumiracoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ALumiracoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Lumiracoxib may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinLumiracoxib may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Lumiracoxib is combined with HE3286.Investigational
HeparinLumiracoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolLumiracoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HydralazineLumiracoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Hygromycin BLumiracoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ibandronate.Approved, Investigational
IdarubicinLumiracoxib may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxLumiracoxib may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Lumiracoxib.Investigational
IndalpineIndalpine may increase the antiplatelet activities of Lumiracoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lumiracoxib.Approved
IndenololLumiracoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Lumiracoxib can be decreased when combined with Indinavir.Approved
INNO-206Lumiracoxib may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Lumiracoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinLumiracoxib may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoniazidThe metabolism of Lumiracoxib can be decreased when combined with Isoniazid.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Istaroxime.Investigational
KanamycinLumiracoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KetoconazoleThe metabolism of Lumiracoxib can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLumiracoxib may decrease the antihypertensive activities of Labetalol.Approved
LandiololLumiracoxib may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Lumiracoxib.Investigational
LeflunomideThe metabolism of Lumiracoxib can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinLumiracoxib may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanLumiracoxib may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololLumiracoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinLumiracoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Lumiracoxib.Approved
LidocaineThe metabolism of Lumiracoxib can be decreased when combined with Lidocaine.Approved, Vet Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Lumiracoxib.Approved, Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Lumiracoxib.Approved
LobeglitazoneThe metabolism of Lumiracoxib can be decreased when combined with Lobeglitazone.Approved, Investigational
LopinavirThe metabolism of Lumiracoxib can be increased when combined with Lopinavir.Approved
LosartanThe metabolism of Lumiracoxib can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Lumiracoxib can be decreased when combined with Lovastatin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LuliconazoleThe serum concentration of Lumiracoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lumiracoxib can be decreased when it is combined with Lumacaftor.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Lumiracoxib.Vet Approved
ManidipineThe metabolism of Lumiracoxib can be decreased when combined with Manidipine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Lumiracoxib is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Medrysone.Approved
MelagatranLumiracoxib may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Melengestrol.Vet Approved
MepindololLumiracoxib may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineLumiracoxib may increase the nephrotoxic activities of Mesalazine.Approved
MestranolLumiracoxib may increase the thrombogenic activities of Mestranol.Approved
MethallenestrilLumiracoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Lumiracoxib.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Lumiracoxib.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Methylprednisolone.Approved, Vet Approved
MetipranololLumiracoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lumiracoxib.Approved
MetoprololLumiracoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideLumiracoxib may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MexiletineThe metabolism of Lumiracoxib can be decreased when combined with Mexiletine.Approved
MicronomicinLumiracoxib may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Lumiracoxib can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Lumiracoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Lumiracoxib.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Lumiracoxib.Approved
MoclobemideThe metabolism of Lumiracoxib can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Lumiracoxib can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Lumiracoxib.Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Lumiracoxib.Approved
MoxestrolLumiracoxib may increase the thrombogenic activities of Moxestrol.Experimental
NadololLumiracoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinLumiracoxib may increase the anticoagulant activities of Nadroparin.Approved
NafamostatLumiracoxib may increase the anticoagulant activities of Nafamostat.Approved, Investigational
Nalidixic AcidLumiracoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Lumiracoxib is combined with NCX 1022.Investigational
NeamineLumiracoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NefazodoneNefazodone may increase the antiplatelet activities of Lumiracoxib.Approved, Withdrawn
NelfinavirThe metabolism of Lumiracoxib can be decreased when combined with Nelfinavir.Approved
NemonoxacinLumiracoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinLumiracoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NetilmicinLumiracoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NevirapineThe metabolism of Lumiracoxib can be decreased when combined with Nevirapine.Approved
NicardipineThe metabolism of Lumiracoxib can be decreased when combined with Nicardipine.Approved
NorfloxacinLumiracoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Lumiracoxib.Approved, Investigational
OlsalazineLumiracoxib may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Lumiracoxib.Investigational
OmeprazoleThe metabolism of Lumiracoxib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Lumiracoxib can be decreased when it is combined with Osimertinib.Approved
OtamixabanLumiracoxib may increase the anticoagulant activities of Otamixaban.Investigational
Oxolinic acidLumiracoxib may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololLumiracoxib may decrease the antihypertensive activities of Oxprenolol.Approved
PamidronateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pamidronate.Approved
PantoprazoleThe metabolism of Lumiracoxib can be decreased when combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Paramethasone.Approved
ParomomycinLumiracoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
PazufloxacinLumiracoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinLumiracoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Lumiracoxib can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololLumiracoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateLumiracoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Lumiracoxib.Approved
PhenindioneLumiracoxib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Lumiracoxib can be increased when combined with Phenobarbital.Approved
PhenprocoumonLumiracoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe metabolism of Lumiracoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PindololLumiracoxib may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidLumiracoxib may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinLumiracoxib may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideLumiracoxib may decrease the diuretic activities of Piretanide.Experimental
Piromidic acidLumiracoxib may increase the neuroexcitatory activities of Piromidic acid.Experimental
PlazomicinLumiracoxib may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinLumiracoxib may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Polyestradiol phosphateLumiracoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Lumiracoxib.Approved
PractololLumiracoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Lumiracoxib.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Lumiracoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Lumiracoxib can be increased when it is combined with Probenecid.Approved
PromestrieneLumiracoxib may increase the thrombogenic activities of Promestriene.Investigational
PropranololLumiracoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Lumiracoxib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Lumiracoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Lumiracoxib.Vet Approved
Protein CLumiracoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanLumiracoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeLumiracoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinLumiracoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinLumiracoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Lumiracoxib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Lumiracoxib.Approved, Investigational
QuinestrolLumiracoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Lumiracoxib.Approved
QuinineThe metabolism of Lumiracoxib can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Lumiracoxib.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Lumiracoxib.Approved
ReviparinLumiracoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinLumiracoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Lumiracoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Lumiracoxib can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Risedronate.Approved, Investigational
RivaroxabanLumiracoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RopiniroleThe metabolism of Lumiracoxib can be decreased when combined with Ropinirole.Approved, Investigational
RosoxacinLumiracoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinLumiracoxib may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinLumiracoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Lumiracoxib.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Lumiracoxib.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Lumiracoxib.Investigational
SecobarbitalThe metabolism of Lumiracoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolLumiracoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SertralineSertraline may increase the antiplatelet activities of Lumiracoxib.Approved
SildenafilThe metabolism of Lumiracoxib can be decreased when combined with Sildenafil.Approved, Investigational
SimeprevirThe metabolism of Lumiracoxib can be decreased when combined with Simeprevir.Approved
SisomicinLumiracoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinLumiracoxib may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Lumiracoxib.Approved
SorafenibThe metabolism of Lumiracoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolLumiracoxib may decrease the antihypertensive activities of Sotalol.Approved
SP1049CLumiracoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinLumiracoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinLumiracoxib may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Lumiracoxib.Approved
SpironolactoneLumiracoxib may decrease the antihypertensive activities of Spironolactone.Approved
StiripentolThe metabolism of Lumiracoxib can be decreased when combined with Stiripentol.Approved
StreptomycinLumiracoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinLumiracoxib may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Lumiracoxib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Lumiracoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Lumiracoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideLumiracoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Lumiracoxib.Investigational
Synthetic Conjugated Estrogens, ALumiracoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BLumiracoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusLumiracoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Lumiracoxib.Approved
TalinololLumiracoxib may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Lumiracoxib.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Lumiracoxib.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Lumiracoxib.Approved, Investigational
TemafloxacinLumiracoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Lumiracoxib.Experimental, Investigational
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Lumiracoxib can be decreased when it is combined with Teriflunomide.Approved
TertatololLumiracoxib may decrease the antihypertensive activities of Tertatolol.Experimental
TheophyllineThe metabolism of Lumiracoxib can be decreased when combined with Theophylline.Approved
TiboloneLumiracoxib may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Lumiracoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Lumiracoxib can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololLumiracoxib may decrease the antihypertensive activities of Timolol.Approved
TioclomarolLumiracoxib may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tixocortol.Approved
TobramycinLumiracoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Lumiracoxib can be decreased when combined with Tolbutamide.Approved
TopiramateThe metabolism of Lumiracoxib can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Lumiracoxib can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideLumiracoxib may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Lumiracoxib.Approved
TranylcypromineThe metabolism of Lumiracoxib can be decreased when combined with Tranylcypromine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Lumiracoxib.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Lumiracoxib.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneLumiracoxib may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Lumiracoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Lumiracoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrovafloxacinLumiracoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinLumiracoxib may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Lumiracoxib.Approved
Valproic AcidThe metabolism of Lumiracoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinLumiracoxib may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Lumiracoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Lumiracoxib.Approved
VemurafenibThe serum concentration of Lumiracoxib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Lumiracoxib.Approved
VoriconazoleThe metabolism of Lumiracoxib can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinLumiracoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranLumiracoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Lumiracoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZeranolLumiracoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZimelidineZimelidine may increase the antiplatelet activities of Lumiracoxib.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Lumiracoxib.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Zoledronic acid.Approved
Zoptarelin doxorubicinLumiracoxib may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinLumiracoxib may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
ZucapsaicinThe metabolism of Lumiracoxib can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Take with or without food. Food has no effect on the absorption of the product.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15403
KEGG Drug
D03714
PubChem Compound
151166
PubChem Substance
46506378
ChemSpider
133236
BindingDB
50207446
ChEBI
73044
ChEMBL
CHEMBL404108
Therapeutic Targets Database
DAP000970
PharmGKB
PA164769031
HET
LUR
Wikipedia
Lumiracoxib
ATC Codes
M01AH06 — Lumiracoxib
PDB Entries
4iiz / 4ik6 / 4oty / 4rrw / 4rrx / 4rrz

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentArthralgia / Kidney Failure,Chronic1
3CompletedTreatmentOsteoarthritis of the Knees2
3CompletedTreatmentOsteoarthritis, Hip1
3CompletedTreatmentRheumatoid Arthritis / Synovitis of osteoarthritis1
3CompletedTreatmentSynovitis of osteoarthritis4
4CompletedTreatmentAcute Gouty Arthritis1
4CompletedTreatmentControlled Hypertension / Synovitis of osteoarthritis1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentOsteoarthritis With Controlled Hypertension1
4CompletedTreatmentPain2
4CompletedTreatmentPainful musculoskeletal conditions1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00549 mg/mLALOGPS
logP4.56ALOGPS
logP4.31ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)4.11ChemAxon
pKa (Strongest Basic)-1.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity75.91 m3·mol-1ChemAxon
Polarizability28.53 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9825
Blood Brain Barrier+0.9715
Caco-2 permeable+0.818
P-glycoprotein substrateNon-substrate0.7336
P-glycoprotein inhibitor INon-inhibitor0.7134
P-glycoprotein inhibitor IINon-inhibitor0.9389
Renal organic cation transporterNon-inhibitor0.916
CYP450 2C9 substrateNon-substrate0.7247
CYP450 2D6 substrateNon-substrate0.8639
CYP450 3A4 substrateNon-substrate0.5964
CYP450 1A2 substrateInhibitor0.5208
CYP450 2C9 inhibitorInhibitor0.6844
CYP450 2D6 inhibitorNon-inhibitor0.8163
CYP450 2C19 inhibitorNon-inhibitor0.8576
CYP450 3A4 inhibitorNon-inhibitor0.8063
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6222
Ames testNon AMES toxic0.8453
CarcinogenicityNon-carcinogens0.6326
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity3.5160 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9512
hERG inhibition (predictor II)Non-inhibitor0.7169
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminotoluenes. These are organic aromatic compounds containing a benzene that carries a single methyl group and one amino group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Toluenes
Direct Parent
Aminotoluenes
Alternative Parents
Aniline and substituted anilines / Fluorobenzenes / Chlorobenzenes / Aryl fluorides / Aryl chlorides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds
show 5 more
Substituents
Aminotoluene / Aniline or substituted anilines / Chlorobenzene / Fluorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Amino acid or derivatives / Amino acid
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organofluorine compound, monocarboxylic acid, organochlorine compound, secondary amino compound, amino acid (CHEBI:73044)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Capone ML, Tacconelli S, Sciulli MG, Patrignani P: Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58. [PubMed:14552704]
  2. Tacconelli S, Capone ML, Patrignani P: Clinical pharmacology of novel selective COX-2 inhibitors. Curr Pharm Des. 2004;10(6):589-601. [PubMed:14965322]
  3. Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ: Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatol. 2004 Feb;2(2):113-20. [PubMed:15017615]
  4. Kalbag J, Yeh CM, Milosavljev S, Lasseter K, Oberstein S, Rordorf C: No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor. Pharmacol Res. 2004 Aug;50(2):181-6. [PubMed:15177307]
  5. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ: Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50. [PubMed:15655513]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Capone ML, Tacconelli S, Sciulli MG, Patrignani P: Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58. [PubMed:14552704]
  2. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ: Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50. [PubMed:15655513]
  3. Jermany J, Branson J, Schmouder R, Guillaume M, Rordorf C: Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. J Clin Pharmacol. 2005 Oct;45(10):1172-8. [PubMed:16172182]
  4. Warner TD, Vojnovic I, Bishop-Bailey D, Mitchell JA: Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J. 2006 Mar;20(3):542-4. Epub 2006 Jan 10. [PubMed:16403783]
  5. Blobaum AL, Marnett LJ: Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90. Epub 2007 Apr 12. [PubMed:17434872]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on May 17, 2007 10:57 / Updated on November 09, 2017 02:58